Evaxion Biotech awarded Eurostars grant to develop a therapeutic antibody against drug-resistant Klebsiella pneumoniae.

Evaxion is leading a Pan-European Consortium to develop a therapeutic antibody against drug-resistant Klebsiella pneumonia. The Consortium, consisting of five partners; Evaxion Biotech, MAB Discovery, Karolinska Institute, Pepscan Therapeutics and Preclin Biosystems, receives €1,6 Million Eurostars Grant for the project “Selection and development of a therapeutic antibody against drug-resistant Klebsiella Pneumoniae”. The Consortium combines unique knowledge and expertise in drug development to develop and perform the preclinical validation of an innovative therapeutic strategy against antibiotic-resistant Klebsiella pneumoniae infections within 3 years from initiation of the work, planned to start January 2018.

Recent News